Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 1c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus
February 26, 2021 6:06 AM ESTAmneal Pharmaceuticals (: AMRX) reported Q4 EPS of $0.14, $0.01 better than the analyst estimate of $0.13. Revenue for the quarter came in at $510 million versus the consensus estimate of $504.44 million.
"We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal," said Chirag and... More
